Brief: Protagonist Therapeutics-Eligible To Get $60M In Milestone Payments In Q4

Protagonist Therapeutics

09/10/2023 13:43

Oct 9 (Reuters) - Johnson & Johnson  JNJ.N :
    * PROTAGONIST THERAPEUTICS-ELIGIBLE TO GET $60M IN MILESTONE
PAYMENTS IN Q4 FOR ADVANCEMENT OF JNJ-2113 INTO MULTIPLE
CLINICAL PROGRAMS LED BY JANSSEN
    * PROTAGONIST THERAPEUTICS INC - REMAINS ELIGIBLE FOR UP TO
$795
MILLION IN OTHER DEVELOPMENT AND SALES MILESTONE PAYMENTS WITH
RESPECT TO JNJ-2113
    * PROTAGONIST THERAPEUTICS INC - ADDITIONAL PHASE 3 STUDIES
WILL
BE INITIATED IN Q1 OF 2024 AS PART OF BROADER PSORIASIS ICONIC
CLINICAL PROGRAM
    * PROTAGONIST THERAPEUTICS INC - TO ALSO EARN UPWARD TIERING
ROYALTIES OF 6%-10%, WITH 10% TIER APPLICABLE FOR NET SALES OF
GREATER THAN $4 BILLION


Further company coverage:  JNJ.N 

 ((Reuters.Briefs@thomsonreuters.com;))